GLIATECH

Gliatech Inc. (NASDAQ: GLIA) was founded in 1988 to discover, develop, and commercialize therapeutic products based on the properties of glial cells. Glial cells perform key roles in the formation and function of the central nervous system (CNS). Gliatech has two separate development programs. The first is focused on the development of ADCON® (adhesion control) gels and solutions, classified as medical devices, that inhibit the formation of postsurgical scarring and adhesions. The second program is based on the development of small molecule drug candidates for the treatment of specific CNS disorders such as Alzheimer's disease, Attention Deficit Hyperactive Disorder (ADHD), and narcolepsy.